Literature DB >> 28323149

The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa.

Faeze Mahdiun1, Shahla Mansouri2, Payam Khazaeli3, Rasoul Mirzaei4.   

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen, enable of causing infections especially in immunocompromised patients. Recently many isolates developed multiple drug resistance, resulting in treatment failure in serious infections. In this study, the effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm production by P. aeruginosa was evaluated. Thin layer hydration method with cholesterol (30%), Span 40 and Tween 40 were used to make niosomes. The physical properties and particle size of the niosomes were investigated. Micro dilution method was used to determine the Minimum Inhibitory Concentration (MIC) for tobramycin, niosomal tobramycin, bismuth ethanedithiol, niosomal bismuth ethanedithiol, tobramycin incorporated with bismuth-ethanedithiol and niosomal tobramycin incorporated with bismuth-ethanedithiol. Biofilm formation was evaluated using microtiter plate. The effect of different combination on N-acyl homoserine lactone (AHL) production was evaluated in presence of Agrobacterium tumefaciens strain (GV3101). The best combination inhibiting the growth of various strains of P. aeruginosa were niosomal tobramycin and niosomal tobramycin incorporated with bismuth-ethanedithiol which reduced the MIC of tobramycin significantly. Sub-MIC concentration of these compounds reduced the rate of biofilm formation 80% lower than the untreated bacteria, and effectively inhibited the production of AHL molecule. The prepared formulations containing non-ionic surfactants, can kept the drug and gradually release it. Encapsulation of tobramycin in combination with bismuth-ethanedithiol in niosome had the ability to reduce the MIC of tobramycin and effectively inhibiting the biofilm formation. These combinations can be used as an excellent combination for further evaluation for treatment of infections caused by MDR isolates of P. aeruginosa.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AHL; Biofilm; Bismuth ethanedithiol; Niosome; Pseudomonas aeruginosa; Tobramycin

Mesh:

Substances:

Year:  2017        PMID: 28323149     DOI: 10.1016/j.micpath.2017.03.014

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

Review 1.  Immunometabolism in biofilm infection: lessons from cancer.

Authors:  Rasoul Mirzaei; Niloofar Sabokroo; Yaghoub Ahmadyousefi; Hamid Motamedi; Sajad Karampoor
Journal:  Mol Med       Date:  2022-01-29       Impact factor: 6.354

Review 2.  Nanoparticles for Signaling in Biodiagnosis and Treatment of Infectious Diseases.

Authors:  Clara I Colino; Carmen Gutiérrez Millán; José M Lanao
Journal:  Int J Mol Sci       Date:  2018-05-31       Impact factor: 5.923

Review 3.  microRNAs in human brucellosis: A promising therapeutic approach and biomarker for diagnosis and treatment.

Authors:  Sima Kazemi; Rasoul Mirzaei; Mohammad Sholeh; Sajad Karampoor; Fariba Keramat; Massoud Saidijam; Mohammad Yousef Alikhani
Journal:  Immun Inflamm Dis       Date:  2021-08-27

Review 4.  Role of genetic variants and host polymorphisms on COVID-19: From viral entrance mechanisms to immunological reactions.

Authors:  Abolfazl Adli; Mandana Rahimi; Reza Khodaie; Niloofar Hashemzaei; Sayed M Hosseini
Journal:  J Med Virol       Date:  2022-02-08       Impact factor: 20.693

Review 5.  The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.

Authors:  Saade Abdalkareem Jasim; Roaa Salih Mahdi; Dmitry Olegovich Bokov; Mazin A A Najm; Guzal N Sobirova; Zarnigor O Bafoyeva; Ahmed Taifi; Ola Kamal A Alkadir; Yasser Fakri Mustafa; Rasoul Mirzaei; Sajad Karampoor
Journal:  J Med Virol       Date:  2022-07-23       Impact factor: 20.693

Review 6.  Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.

Authors:  Vo Van Giau; Seong Soo A An; John Hulme
Journal:  Drug Des Devel Ther       Date:  2019-01-18       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.